Open AccessPrevalence of Homologous Recombination–Related Gene Mutations Across Multiple Cancer Types
Author(s) -
Arielle L. Heeke,
Michael J. Pishvaian,
Filipa Lynce,
Joanne Xiu,
Jonathan R. Brody,
Wang Juh Chen,
Tabari Baker,
John L. Marshall,
Claudine Isaacs
Publication year - 2018
Publication title -
jco precision oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.405
H-Index - 22
ISSN - 2473-4284
DOI - 10.1200/po.17.00286
Subject(s) - palb2 , fanca , ercc1 , homologous recombination , bap1 , rad51 , mlh1 , cancer research , gene , biology , dna repair , medicine , genetics , germline mutation , mutation , dna mismatch repair , fanconi anemia , nucleotide excision repair
The prevalence of homologous recombination DNA damage repair (HR-DDR) deficiencies among all tumor lineages is not well characterized. Therapy directed toward homologous recombination DDR deficiency (HRD) is now approved in ovarian and breast cancer, and there may be additional opportunities for benefit for patients with other cancers. Comprehensive evaluations for HRD are limited in part by the lack of a uniform, cost-effective method for testing and defining HRD.